Alto Neuroscience Inc 2026年季度报告

(Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from to . Commission file number 001-41944_________________________ Alto Neuroscience, Inc. (Exact name of registrant as specified in its charter)_________________________ (650) 200-0412Registrant’s Telephone Number, Including Area Code Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to such filing requirements for the past 90 days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act. Large accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YesNo The number of shares of registrant’s Common Stock outstanding as of May8, 2026 was 35,093,940. Table of Contents Part I - Financial Information Item 1. Financial Statements (Unaudited)F-1Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations20Item 3. Quantitative and Qualitative Disclosures About Market Risk35Item 4. Controls and Procedures35 Part II - Other Information Unless context otherwise requires, the terms the “Company,” “Alto,” “we,” “us,” “our,” and similar references in this QuarterlyReport on Form 10-Q refer to Alto Neuroscience, Inc. and its consolidated subsidiary. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements about us and our industry that involvesubstantial risks and uncertainties. All statements other than statements of historical fact contained in this Quarterly Report, includingstatements regarding our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans, orintentions relating to product candidates and markets and business trends are forward-looking statements. We have based theseforward-looking statements largely on our current expectations and projections. In some cases, you can identify forward-lookingstatements because they contain words such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “design,”“estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “shall,” “should,” “target,”“will,” or “would,” or the negative of these words or other similar terms or expressions. These statements involve known and unknown risks, uncertainties, and other factors which may cause our actual results, performanceor achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: •the initiation, timing, progress, and results of our research and development programs, preclinical studies, any clinicaltrials, and investigational new drug, or IND, and other regulatory submissions; •the ability of our approach to reproducibly predict treatment outcomes for product candidates amongst identified patientpopulations and achieve clinical success;•our ability to continue to identify appropriate biomarkers for use in further clinical development;•the timing of and costs involved in obtaining and maintaining regulatory approval of our current product candidates andany future product candidates that we may identify or develop;•the beneficial characteristics, including potential safety, efficacy, and therapeutic effects, of our product candidates;•our ability to efficiently and cost-effectively conduct our current and future clinical trials;•our ability to obtain funding for our operations necessary to complete further development and commercialization of